Navigation Links
3D0817 Prefilled Dispoable Nebulizer

Products3D0817 Prefilled Dispoable Nebulizer
Company Cardinal Health, Inc.
Item 3D0817 Prefilled Dispoable Nebulizer
Features 
  • Nebulizer
  • Disposable
  • Prefilled
  • 28%-100% FIO2
  • 500ML 0.45% Sodium Chloride
  • 12 per case
  • Prescription Device
  • Latex Free
  • Sterile
Description Nebulizer Disposable Prefilled 28%-100% FIO2 500ML 0.45% Sodium Chloride

Our prefilled nebulizers provide unmatched performance and ease of use. You can obtain heated and cool high-output aerosols adjustable from 28% to 100% FIO2. We offer a wide selection of solutions: sterile water for inhalation, USP; 0.45% sodium chloride inhalation, USP; and 0.9% sodium chloride inhalation, USP. Easy setup includes an aluminum heat exchange system and external slip-on heaters (sold separately), which heat the aerosol while reducing the possibility of contamination.
Info Cardinal Health, Inc.
Customer Service: (800) 234-8701
Web site: http://www.cardinal.com

Related medicine products :

1. AL2500 AirLife™ Prefilled Humidifier Systems
2. 3D0828 Prefilled Dispoable Nebulizer
3. 3D0827 Prefilled Dispoable Nebulizer
4. 3D0808 Prefilled Dispoable Nebulizer
5. 3D0818 Prefilled Dispoable Nebulizer
6. 3D0807 Prefilled Dispoable Nebulizer
7. Nebulizer Prefilled 1000ML Sterile H2O W/O Adapter
8. DeVilbiss Pulmo-Aide® Compact Compressor/Nebulizer With Reusable Neb
9. DeVilbiss Pulmo-Aide® Compact Compressor/Nebulizer With Disposable Neb
10. TransNeb™ Compact Compressor/Nebulizer System
11. SportNeb™ Ultra Light Nebulizer/Compressor
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Millions Flowing into Medical Real Estate 13292 1Millions Flowing into Medical Real Estate 13292 2Millions Flowing into Medical Real Estate 13292 3Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 1Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 2